WO1998009519A1 - Methode destinee a traiter des maladies post-menopausiques, dont l'osteoporose - Google Patents

Methode destinee a traiter des maladies post-menopausiques, dont l'osteoporose Download PDF

Info

Publication number
WO1998009519A1
WO1998009519A1 PCT/US1997/015474 US9715474W WO9809519A1 WO 1998009519 A1 WO1998009519 A1 WO 1998009519A1 US 9715474 W US9715474 W US 9715474W WO 9809519 A1 WO9809519 A1 WO 9809519A1
Authority
WO
WIPO (PCT)
Prior art keywords
idoxifene
estrogen
bone
osteoporosis
ere
Prior art date
Application number
PCT/US1997/015474
Other languages
English (en)
Inventor
Maxine Gowen
Jeremy N. Bradbeer
Original Assignee
Smithkline Beecham Corporation
BEESLEY, Jacqueline
BRADBEER, Richard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, BEESLEY, Jacqueline, BRADBEER, Richard filed Critical Smithkline Beecham Corporation
Priority to EP97940773A priority Critical patent/EP0929216A4/fr
Priority to IL12864597A priority patent/IL128645A0/xx
Priority to CA002264775A priority patent/CA2264775A1/fr
Priority to AU42473/97A priority patent/AU4247397A/en
Priority to BR9711676A priority patent/BR9711676A/pt
Priority to JP51283798A priority patent/JP2002515046A/ja
Priority to CZ99766A priority patent/CZ76699A3/cs
Publication of WO1998009519A1 publication Critical patent/WO1998009519A1/fr
Priority to NO991097A priority patent/NO991097D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne une nouvelle méthode destinée à traiter l'ostéoporose. L'idoxifène est le composé préféré.
PCT/US1997/015474 1996-09-06 1997-09-03 Methode destinee a traiter des maladies post-menopausiques, dont l'osteoporose WO1998009519A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP97940773A EP0929216A4 (fr) 1996-09-06 1997-09-03 Methode destinee a traiter des maladies post-menopausiques, dont l'osteoporose
IL12864597A IL128645A0 (en) 1996-09-06 1997-09-03 Method of treating post menopausal diseases including osteoporosis
CA002264775A CA2264775A1 (fr) 1996-09-06 1997-09-03 Methode de traitement des maladies post-menopausiques, dont l'osteoporose
AU42473/97A AU4247397A (en) 1996-09-06 1997-09-03 Method of treating post menopausal diseases, including osteoporosis
BR9711676A BR9711676A (pt) 1996-09-06 1997-09-03 M-todo de tratamento de doen-asd pÄs-menop usicas incluindo osteoporose
JP51283798A JP2002515046A (ja) 1996-09-06 1997-09-03 骨粗鬆症を含む閉経後疾患を治療する方法
CZ99766A CZ76699A3 (cs) 1996-09-06 1997-09-03 Způsob léčení postmenopauzálních chorob, včetně osteoporozy
NO991097A NO991097D0 (no) 1996-09-06 1999-03-05 Nye fremgangsmÕter

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2543996P 1996-09-06 1996-09-06
US5066697P 1997-06-24 1997-06-24
US60/025,439 1997-06-24
US60/050,666 1997-06-24

Publications (1)

Publication Number Publication Date
WO1998009519A1 true WO1998009519A1 (fr) 1998-03-12

Family

ID=26699738

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1997/015475 WO1998009619A1 (fr) 1996-09-06 1997-09-03 Procedes nouveaux
PCT/US1997/015474 WO1998009519A1 (fr) 1996-09-06 1997-09-03 Methode destinee a traiter des maladies post-menopausiques, dont l'osteoporose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015475 WO1998009619A1 (fr) 1996-09-06 1997-09-03 Procedes nouveaux

Country Status (16)

Country Link
EP (2) EP0927029A4 (fr)
JP (2) JP2002515047A (fr)
KR (2) KR20000068473A (fr)
CN (2) CN1236299A (fr)
AR (1) AR008155A1 (fr)
AU (2) AU4409797A (fr)
BR (2) BR9711681A (fr)
CA (2) CA2264943A1 (fr)
CO (2) CO4920218A1 (fr)
CZ (1) CZ76699A3 (fr)
IL (1) IL128645A0 (fr)
NO (2) NO991096L (fr)
PL (2) PL332278A1 (fr)
TR (2) TR199900504T2 (fr)
TW (1) TW411273B (fr)
WO (2) WO1998009619A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034608A1 (fr) * 1997-02-11 1998-08-13 Novo Nordisk A/S Methodes therapeutiques ou prophylactiques a l'encontre de symptomes menopausiques
WO2001077057A2 (fr) * 2000-04-05 2001-10-18 Dupont Pharmaceuticals Company Derives de triphenylethylene halogene utiles en tant que modulateurs selectifs vis-a-vis du recepteur des oestrogenes

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260066B1 (fr) * 1986-09-11 1990-05-09 National Research Development Corporation Dérivés du tamoxifène
AU672234B2 (en) * 1992-09-15 1996-09-26 Merrell Dow Pharmaceuticals Inc. Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PROMT ON STN, PROMT No. 95:72927, British Technology Group; SmithKline Beecham PLC, In Vivo the Business & Medicine Report, January 1995, page 66. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034608A1 (fr) * 1997-02-11 1998-08-13 Novo Nordisk A/S Methodes therapeutiques ou prophylactiques a l'encontre de symptomes menopausiques
WO2001077057A2 (fr) * 2000-04-05 2001-10-18 Dupont Pharmaceuticals Company Derives de triphenylethylene halogene utiles en tant que modulateurs selectifs vis-a-vis du recepteur des oestrogenes
WO2001077057A3 (fr) * 2000-04-05 2002-06-13 Du Pont Pharm Co Derives de triphenylethylene halogene utiles en tant que modulateurs selectifs vis-a-vis du recepteur des oestrogenes

Also Published As

Publication number Publication date
KR20000068473A (ko) 2000-11-25
PL332278A1 (en) 1999-08-30
PL332038A1 (en) 1999-08-16
NO991096D0 (no) 1999-03-05
EP0929216A4 (fr) 2001-04-04
TR199900506T2 (xx) 1999-07-21
CN1236313A (zh) 1999-11-24
AU4247397A (en) 1998-03-26
TR199900504T2 (xx) 1999-06-21
CA2264775A1 (fr) 1998-03-12
EP0927029A1 (fr) 1999-07-07
NO991096L (no) 1999-03-05
NO991097L (no) 1999-03-05
AR008155A1 (es) 1999-12-09
NO991097D0 (no) 1999-03-05
JP2002515046A (ja) 2002-05-21
CN1236299A (zh) 1999-11-24
CO5070658A1 (es) 2001-08-28
CZ76699A3 (cs) 1999-08-11
BR9711676A (pt) 1999-08-24
IL128645A0 (en) 2000-01-31
CO4920218A1 (es) 2000-05-29
TW411273B (en) 2000-11-11
AU4409797A (en) 1998-03-26
BR9711681A (pt) 1999-08-24
KR20000068472A (ko) 2000-11-25
EP0927029A4 (fr) 2001-06-13
EP0929216A1 (fr) 1999-07-21
WO1998009619A1 (fr) 1998-03-12
CA2264943A1 (fr) 1998-03-12
JP2002515047A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
Ke et al. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model
EP1438957B1 (fr) Raloxifène destinée au traitement de l'ostéoporose post-ménopause
Mitlak et al. Selective estrogen receptor modulators: a look ahead
KR101141763B1 (ko) 체중 증가의 치료 및/또는 억제에 사용하는 약학 조성물
KR100278946B1 (ko) 혈청 콜레스테롤을 저하시키는데 유용한 벤조티오펜
Evans et al. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia
HUT72638A (en) Pharmaceutical compositions containing benzotiophene derivative for inhibiting bone loss and for lowering serum cholesterol and process for its preparation
HOL et al. Selective estrogen receptor modulators and postmenopausal women's health
US4970237A (en) Use of clomiphene to increase bone mass in premenopausal women
CA2223055A1 (fr) Procedes pour minimiser les pertes osseuses
WO1998009519A1 (fr) Methode destinee a traiter des maladies post-menopausiques, dont l'osteoporose
US4820736A (en) Use of clomiphene to predict fertility in a human female
EP1140047B1 (fr) Hormonotherapie du cancer du sein associee a un traitement au tamoxifene et aux dibenzofurannes polychlores alkyles
MXPA99002213A (en) Method of treating post menopausal diseases, including osteoporosis
EP0747056B1 (fr) Diminuer la perte osseuse par des combinaisons d'anti-estrogènes
WO1999000019A1 (fr) Procedes de traitement des symptomes de la vaginite atrophique et du comportement sexuel modifie chez des femmes postmenopausees
Goulding et al. Effects of clomiphene and tamoxifen in vivo on the bone-resorbing effects of parathyroid hormone and of high oral doses of calcitriol (1, 25 (OH) 2D3) in rats with intact ovarian function consuming low calcium diet
PL186085B1 (pl) Stosowanie antyestrogenów do kontroli płodności męskiej
Lamarca The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis
AL-GANZOURY et al. Effect of estrogen agonist antagonist on bone mineral density in postmenopausal breast cancer
Tau et al. Marked recovery from axial osteopenia in children with liver transplantation
WO1998049896A1 (fr) Methode de traitement de symptomes vasomoteurs
MXPA99002214A (en) Novel methods
WO1999000018A1 (fr) Methodes de traitement des symptomes de troubles de la memoire, de la concentration et de la cognition chez la femme menauposee

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199492.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR CA CN CZ EE GE GH HU IL IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 334330

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1999-766

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2264775

Country of ref document: CA

Ref document number: 2264775

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1998 512837

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/002213

Country of ref document: MX

Ref document number: 1019997001860

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999/00504

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1997940773

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997940773

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-766

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1999-766

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997001860

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997940773

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997001860

Country of ref document: KR